DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Dr Georgina Harvey, Dermatology Registrar, Waikato Hospital, Hamilton, New Zealand; Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, October 2015.
Acrokeratosis verruciformis of Hopf is a rare genodermatosis classified as a disorder of keratinisation. It is often considered to be a variant of Darier disease. It was first identified in 1931 by Dr Gustav Hopf, a German dermatologist.
Acrokeratosis verruciformis of Hopf is due to an abnormal ATP2A2 gene. It has autosomal dominant inheritance, meaning that only one copy of the affected gene needs to be inherited to develop the disease. If one parent is affected, the chance of a child developing acrokeratosis verruciformis of Hopf is 1 in 2 (50%).
Mutations in ATP2A2 also cause Darier disease. The gene encodes the sarcoplasmic reticulum calcium ATPase 2 pump, controlling intracellular calcium. It is hypothesised that impaired functioning of this pump alters the ability of desmosomes to link keratinocytes together.
Acrokeratosis verruciformis of Hopf is characterised by multiple, flat-topped, symmetrical, skin coloured keratotic lesions on the dorsum of the hands and feet. These are usually present from birth or early childhood but occasionally arise in adult life. Other features may include:
The skin changes in acrokeratosis verruciformis of Hopf are asymptomatic and rarely lead to any complications.
Acrokeratosis verruciformis of Hopf is diagnosed clinically. This is easier if there are family members with similar skin findings. Sometimes a skin biopsy is performed to assist with the diagnosis.
The key features on histology are hyperkeratosis, acanthosis, papillomatosis and a thickened granular layer. Rarely, acantholysis is seen. Circumscribed epidermal elevations, known as 'church spires' are a distinctive finding. See Darier disease pathology.
As acrokeratosis verruciformis of Hopf is asymptomatic and localised, no treatment is required. If a patient prefers treatment for cosmetic reasons, destruction of the papules can be performed with cryotherapy or a destructive laser. Topical tretinoin has also been used to reduce the thickness of the papules.
See the DermNet NZ bookstore
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.